XAGE
Longevity Health Holdings, Inc. Common StockXAGE
XAGE
About: Longevity Health Holdings Inc is a United States based bio-aesthetics company focused on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company has two cosmetic product lines, Carmell Secretome and Elevai Exosomes, that support skin and hair health.
Employees: 13
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 22 [Q4 2024] → 23 (+1) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
2.75% less ownership
Funds ownership: 6.32% [Q4 2024] → 3.58% (-2.75%) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
64% less capital invested
Capital invested by funds: $374K [Q4 2024] → $135K (-$239K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for XAGE.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Longevity Health Holdings, Inc. Announces Successful Fundraising Via ATM Sale
Pittsburgh, PA, May 27, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) (“XAGE,” the “Company,” “we” or “our”), a company dedicated to advancing human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition, today announced the successful sale of 479,621 shares of its common stock at an average price of $4.08 per share through its at-the-market (ATM) equity offering facility. Gross proceeds from the ATM sales totaled approximately $1.96 million, prior to deducting fees and expenses.
Neutral
GlobeNewsWire
3 weeks ago
Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs
PITTSBURGH, May 21, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE) (“XAGE,” the “Company,” “we,” “us,” or “our”), a company focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition, today announced that it has received a favorable decision from the Nasdaq Hearings Panel (the “Panel”) granting the Company's request to continue its listing on The Nasdaq Stock Market (“Nasdaq”) subject to the satisfaction of the Nasdaq initial listing rules for the combined company following the proposed merger with 20/20 BioLabs, Inc. (“20/20”) on or before September 2, 2025. This decision follows the Panel's comprehensive review of the Company's recent business developments, financial disclosures, and proposed merger with 20/20.
Neutral
GlobeNewsWire
1 month ago
Longevity Health Holdings Announces Business Updates
PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“XAGE”, the “Company”, “we”, “our”, or “us”), today announced the following business updates: 1.
Neutral
GlobeNewsWire
1 month ago
Longevity Health Holdings, Inc. Announces Reverse Stock Split
PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc . (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has resolved to effect a reverse stock split of the Company's common stock and has determined the ratio to be 1-for-30. The Company's stockholders approved the reverse stock split and granted the Longevity board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company's Special Meeting of Stockholders held on March 24, 2025.
Charts implemented using Lightweight Charts™